NIH grants Eko $2.7M to develop pulmonary hypertension AI tech

[Image from Eko]Eko announced today that it received a $2.7 million Small Business Innovation Research (SBIR) Direct Phase II grant.

The National Institutes of Health’s (NIH) Department of Health and Human Services (HHS) awarded the grant. The grant will fund the development of a machine learning algorithm, according to a news release.

Eko said the algorithm detects and stratifies pulmonary hypertension (PH). It uses phonocardiogram (PCG) and electrocardiogram (ECG) data from Eko’s smart stethoscopes. To address challenges of ECG-based AI models for detecting PH, Eko partnered with Lifespan Health System’s Cardiovascular Institute.

The partnership collects real-world PCG and ECG data using the Eko Duo ECG + digital stethoscope. Eko plans to use the data to develop an algorithm that can detect PH and stratify its severity. Early identification can diagnose PH earlier and more accurately, leading to potentially life-saving interventions.

Read more
  • 0

Caregility, Eko partner to bring smart stethoscope to telehealth platform

[Image from Eko and Caregility]Caregility and Eko announced today that they entered into a partnership to integrate cloud technology and smart stethoscopes.

The partnership enables seamless integration between Caregility’s cloud platform and Eko’s smart stethoscopes and software. The idea is to allow health providers on Caregility’s iConsult application to perform auscultation (heart, lung, and other body sounds) on patients during a virtual physical exam.

“Our partnership addresses a key component missing from most virtual exams – auscultation. The ability for care teams to easily and accurately assess a patient’s body sounds in real-time will have a meaningful impact on our hybrid care delivery models, including telenursing, telerounding, tele-ICU, and at-home care,” Peter McLain, chief strategy officer and SVP of business development at Caregility, said in a news release. “Eko’s unparalleled digital stethoscope so…

Read more
  • 0

FDA clears Eko’s AI for detecting heart disease

[Image from Eko]Eko announced today that it received FDA clearance for its Eko Murmur Analysis Software (EMAS) for adult and pediatric patients.

The next generation of Eko’s murmur detection capabilities, EMAS represents the first and only smart stethoscope on the market that can identify and differentiate between innocent and structural heart murmurs indicative of valvular heart disease.

According to a news release, Eko has transformed the traditional stethoscope into an objective, low-cost and scalable screening tool that can identify significant structural heart disease within seconds on the front lines of care. The company has collaborated in with 3M to connect its software and artificial intelligence algorithms and help clinicians use 3M’s stethoscope to better interpret sounds and detect heart murmurs, too.

“This latest FDA clearance is another way in which Eko is improving access to better heart health through clinically-validated algorit…

Read more
  • 0

Eko launches screening app for early heart disease detection

Eko announced today that it launched its newly redesigned Eko application that aids in screening for cardiovascular disease.

Oakland, California-based Eko develops smart stethoscopes to pair with its accompanying automated disease detection software with the Eko app for analyzing heart sounds with FDA-cleared artificial intelligence (AI)-powered algorithms.

According to a news release, Eko aims to utilize the newly redesigned app to transform patient interactions into an opportunity to screen for cardiovascular disease, with the AI algorithms capable of detecting heart murmurs and AFib within seconds.

The AI algorithm was clinically validated to perform at a sensitivity of 87.6% and specificity of 87.8% in identifying heart murmurs, with Eko’s AFib algorithm producing a sensitivity of 98.9% and specificity of 96.9%.

Dr. Joanna Kmiecik, a family medicine specialist in Chicago, said in the release that Eko’s products offer ease of use an…

Read more
  • 0

Eko lands $2.7m federal grant for heart disease detection study

Eko announced today that it received a $2.7 million Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH).

Oakland, Calif.-based Eko said in a news release that the grant will be used to fund its collaborative work with Northwestern Medicine Bluhm Cardiovascular Institute as they validate algorithms to help screen for pathologic heart murmurs and valvular heart disease during routine office visits.

Eko and Northwestern announced their collaboration in March 2019 in an effort to find a low-cost option for identifying patients with heart disease without screening tools like echocardiograms.

This year alone, Eko received FDA approval in January for its suite of algorithms that combine with the company’s digital stethoscopes to screen for heart conditions, then in March it won FDA emergency use authorization for its novel ECG-based algorithm that screens for low ejection fraction in COVID-19 patients.

“This SBIR …

Read more
  • 0

Eko names Humbarger as new SVP

Eko announced yesterday that it appointed Bryan Humbarger as its new senior vice president of commercial with an emphasis on sales.

The digital health sales veteran’s new role includes responsibilities for overseeing sales and commercial operations for Eko’s AI and telemedicine software platforms for health systems, practices and providers worldwide, according to a news release.

“Eko’s next generation of cardiac and pulmonary solutions are already making a difference for providers and their patients, and I am thrilled to bring my experience in cardiology and digital health to further accelerate the adoption of Eko’s technology,” Humbarger said in the release. “Being at the forefront of delivering what’s next in cardiovascular care is my passion, and I am thrilled to continue this journey at Eko, a company making a difference in how cardiac and pulmonary care is delivered.”

Oakland, Calif.-based Eko welcomes Humbarger on the back of FDA cleara…

Read more
  • 0